Biological Reproductive Health

Menopur

Payments companies reported to CMS as associated with Menopur. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.5Massociated payments (2023-2025)

2,002clinicians with associated payments

5companies reporting

By year

2023 $657K

2024 $451K

2025 $382K

Payments reported as associated with Menopur, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Reproductive Endocrinology $1.1M

Family $90K

Obstetrics & Gynecology $73K

Physician Assistant $48K

Women'S Health (Nurse Practitioner) $48K

Urology $11K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Menopur

These are the largest totals companies reported as associated with Menopur. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Fady Sharara	Reston, VA	Reproductive Endocrinology	$154,677.33
John Park	Raleigh, NC	Reproductive Endocrinology	$70,154.74
Jason Griffith	Spring, TX	Reproductive Endocrinology	$69,690.54
Michael Scheiber	Cincinnati, OH	Reproductive Endocrinology	$67,352.77
Staci Gorson	Chicago, IL	Family	$60,287.02
Roohi Najeemuddin	Chicago, IL	Reproductive Endocrinology	$47,475.30
Lisa Becht	Newport Beach, CA	Reproductive Endocrinology	$40,902.07
Amber Cooper	Saint Louis, MO	Reproductive Endocrinology	$40,476.50
Shana Perman	Washington, DC	Physician Assistant	$35,547.26
Angeline Beltsos	Chicago, IL	Reproductive Endocrinology	$31,834.02

Prescribed Menopur?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.